Vicore Pharma Holding AB
STO:VICO

Watchlist Manager
Vicore Pharma Holding AB Logo
Vicore Pharma Holding AB
STO:VICO
Watchlist
Price: 7.71 SEK -1.91% Market Closed
Market Cap: 1.8B SEK
Have any thoughts about
Vicore Pharma Holding AB?
Write Note

Vicore Pharma Holding AB
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Vicore Pharma Holding AB
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
Vicore Pharma Holding AB
STO:VICO
Income from Continuing Operations
-kr200.1m
CAGR 3-Years
2%
CAGR 5-Years
-20%
CAGR 10-Years
N/A
Biogaia AB
STO:BIOG B
Income from Continuing Operations
kr365.4m
CAGR 3-Years
27%
CAGR 5-Years
11%
CAGR 10-Years
N/A
Bonesupport Holding AB
STO:BONEX
Income from Continuing Operations
kr90.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Vitrolife AB
STO:VITR
Income from Continuing Operations
-kr3.8B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
Income from Continuing Operations
kr3.5B
CAGR 3-Years
6%
CAGR 5-Years
7%
CAGR 10-Years
N/A
BioArctic AB
STO:BIOA B
Income from Continuing Operations
kr229.2m
CAGR 3-Years
N/A
CAGR 5-Years
-10%
CAGR 10-Years
N/A
No Stocks Found

Vicore Pharma Holding AB
Glance View

Market Cap
1.8B SEK
Industry
Biotechnology

Vicore Pharma Holding AB is a pharmaceutical company, which engages in the development of drugs with focus on interstitial lung diseases and related indications. The company is headquartered in Goeteborg, Vastra Gotalands. The company went IPO on 2015-12-10. The firm's portfolio contains small molecules with potential indications, including anti-inflammation, nerve generation and cardiovascular disease. The firm is a wholly owned subsidiary of Mintage Scientific AB.

VICO Intrinsic Value
4.31 SEK
Overvaluation 44%
Intrinsic Value
Price

See Also

What is Vicore Pharma Holding AB's Income from Continuing Operations?
Income from Continuing Operations
-200.1m SEK

Based on the financial report for Jun 30, 2024, Vicore Pharma Holding AB's Income from Continuing Operations amounts to -200.1m SEK.

What is Vicore Pharma Holding AB's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
-20%

Over the last year, the Income from Continuing Operations growth was 24%. The average annual Income from Continuing Operations growth rates for Vicore Pharma Holding AB have been 2% over the past three years , -20% over the past five years .

Back to Top